NASDAQ : NBTX
Nanobiotix S.A. — Key statistics
Healthcare · Biotechnology · France
Last price 31.37 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.60B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.60B |
| Enterprise Value | 1.59B |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 24, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 50.80M |
| Shares Change (YoY) | +2.40% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 3.97% |
| Owned by Institutions (%) | 15.00% |
| Float | 35.15M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 121.37 |
| Forward PS | 20.11 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 121.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.44 |
| Quick Ratio | 1.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.43 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.34% |
| Return on Invested Capital (ROIC) | -66.69% |
| Return on Capital Employed (ROCE) | -69.86% |
| Weighted Average Cost of Capital (WACC) | 8.06% |
| Revenue Per Employee | $134,135 |
| Profits Per Employee | -$616,302 |
| Employee Count | 98 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 14,852 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +74.38% |
| 50-Day Moving Average | 32.53 |
| 200-Day Moving Average | 33.85 |
| Relative Strength Index (RSI) | 55.43 |
| Average Volume (20 Days) | 133,200 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 196,508 |
| Short Previous Month | 146,868 |
| Short % of Shares Out | 0.52% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.31 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 13.15M |
| Gross Profit | 13.15M |
| Operating Income | -33.84M |
| Pretax Income | -60.38M |
| Net Income | -60.40M |
| EBITDA | -34.03M |
| EBIT | -33.84M |
| Loss Per Share | -$1.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 126.69M |
| Total Debt | 121.80M |
| Net Cash | 4.89M |
| Net Cash Per Share | $0.10 |
| Equity (Book Value) | -38.14M |
| Book Value Per Share | -0.75 |
| Working Capital | 42.90M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -38.19M |
| Capital Expenditures | -1.13M |
| Depreciation & Amortization | -185,425 |
| Net Borrowing | 43.05M |
| Free Cash Flow | -39.32M |
| FCF Per Share | -$0.77 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -257.43% |
| Pretax Margin | -459.35% |
| Profit Margin | n/a |
| EBITDA Margin | -258.87% |
| EBIT Margin | -257.43% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.40% |
| Shareholder Yield | -2.40% |
| Earnings Yield | -3.88% |
| FCF Yield | -2.46% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $54.24 |
| Price Target Difference | 72.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 40.84% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.89 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |